NextCure Announces Initiation of Phase Ib/II Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA^® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure, Inc. announced the initiation of a Phase Ib/II clinical trial to evaluate NC410 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with immune checkpoint refractory or immune checkpoint naïve solid tumors.